- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Bennett debuts as unit of ThermoTrex
Bennett X-Ray will mark its first RSNA meeting as a subsidiaryof ThermoTrex Medical, the division formed in September afterLorad parent ThermoTrex Corp. bought Bennett, of Copiague, NY. Don't expect any major changes in Bennett's RSNA booth, as
Bennett X-Ray will mark its first RSNA meeting as a subsidiaryof ThermoTrex Medical, the division formed in September afterLorad parent ThermoTrex Corp. bought Bennett, of Copiague, NY.
Don't expect any major changes in Bennett's RSNA booth, as ThermoTrexplans to allow Lorad and Bennett to maintain their separate identitieswithin ThermoTrex Medical. The two firms will integrate some oftheir imaging technologies, however.
For example, Bennett is developing a line of radiographic equipmentto be sold through Lorad's sales channels. ThermoTrex said Bennett'sexpertise in radiography was a major factor in the company's acquisitionof Bennett. The Bennett systems will be shown in Lorad's boothand will carry the Lorad label.
Bennett has also made a name for itself in digital mammography,and the company will show its latest work in the area. The companywill debut one of its first full-view digital production units,as well as patient images acquired with the system.
In radiography, Bennett will unveil a trauma C-arm designed tobe mounted on a wall rather than a ceiling, in order to save space.The company will show a new line of R&F and fluoroscopic high-fieldgenerators, as well as a prone stereotactic breast biopsy tableto complement its upright stereotactic system.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.
